Open-label Safety And Efficacy Evaluation Of Fx-1006a In Subjects With Transthyretin (Ttr) Amyloidosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Tafamidis meglumine (Primary)
- Indications Amyloidosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Pfizer
- 20 Oct 2017 Planned End Date changed from 1 Dec 2021 to 31 Dec 2021.
- 20 Oct 2017 Planned primary completion date changed from 1 Dec 2021 to 31 Dec 2021.
- 31 Aug 2017 Results published in a Pfizer media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History